G'day Joe,
Two reasons and a gut feeling (the latter is useless of course).
1. Relatlimab - BMS in pole position for first Lag-3 FDA approval in melanoma. BMS are cashed up and may see the opportunity to develop their Lag-3 stable (agonist and antagonist) or possibly take out Immutep completely and thereby gain the pre-eminent focused (pure play) Lag-3 player in the world.
2. Paclitaxel (PTX), sold under the brand name Taxol among others, is a chemotherapy medication used to treat a number of types of cancer. Taxol is made by BMS (see below).
AIPAC phase 3 efti/paclitaxel combo could make sense to partner with BMS. The cost of a P3 trial if we go it alone would cost Immutep circa $30 million.
Scientists isolated paclitaxel, one of the mostly widely used anti-cancer compounds from the bark of the Pacific yew tree in the 1960s. However, it wasn’t until the 1980s that the drug Taxol® was fully developed under the terms of a Cooperative Research and Development Agreement (CRADA) between the National Cancer Institute (NCI) and Bristol-Myers Squibb.
- Forums
- ASX - By Stock
- Ann: Immutep Quarterly Activities Report and Appendix 4C
G'day Joe,Two reasons and a gut feeling (the latter is useless...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $421.2M |
Open | High | Low | Value | Volume |
29.0¢ | 29.0¢ | 29.0¢ | $34.52K | 119.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 103099 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 251285 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 103099 | 0.290 |
19 | 269766 | 0.285 |
21 | 580428 | 0.280 |
9 | 250994 | 0.275 |
10 | 248779 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.295 | 251285 | 8 |
0.300 | 588305 | 3 |
0.305 | 228593 | 9 |
0.310 | 528209 | 7 |
0.315 | 174875 | 8 |
Last trade - 10.04am 11/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online